STAT+: Pfizer’s gene therapy for Duchenne muscular dystrophy fails in phase 3 trial
Pfizer said Wednesday afternoon that a closely watched gene therapy for Duchenne muscular dystrophy failed…
Category: drug development
What do Parkinson’s and obesity have in common?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Eli Lilly’s Alzheimer’s candidate, Bob Langer’s new startup, and other biotech news you need to know
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Vanda Pharmaceuticals has another suitor
Want to stay on top of the science and politics driving biotech today? Sign up to get…
.jpg)
Novovax will be able to supply Covid-19 vaccines this fall
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Testing begins for a new form of PrEP
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Operation Warp Speed but for rare disease
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Can AstraZeneca make good on its promise?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: AstraZeneca’s Tagrisso greatly slows cancer for some people with stage 3 lung cancer
In patients with stage 3 lung cancer where a particular genetic mutation is present in…
STAT+: ASCO Daily Recap: Safety data for Novartis myelofibrosis candidate, survival data for Pfizer drug
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American…
STAT+: At ASCO, pharma leaders explain how ‘smart bomb’ drugs became useful against more cancers
CHICAGO — The ways clinicians can treat cancers effectively are expanding, partly because technologies today…
The surprising outperformance of a new drug against existing competitors, and other biotech updates
Want to stay on top of the science and politics driving biotech today? Sign up to get…
.jpg)
STAT+: Ionis drug prevents swelling attacks caused by rare genetic disease in late-stage trials
Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on…
Biohaven’s autoimmune drug disappoints, and other biotech news updates from the week
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Wegovy linked to lower risk of alcohol use disorder in real-world study
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Biotech’s most interesting fundraisings from the last week
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Gene therapies for deafness dredge up an old question: Do deaf people want a ‘cure’?
When Yilai Shu was training to be an otolaryngologist in Shanghai, in the mid 2000s,…
More tumult at BIO amid the company’s fourth CEO in four years
Want to stay on top of the science and politics driving biotech today? Sign up to get…
In light of H5N1 outbreak, U.S. in talks with mRNA vaccine makers on bird flu
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Biotechs turn to gene silencing for obesity drugs that can last longer than Wegovy
Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a…
STAT+: New antiviral works against coronaviruses in mice, but human testing will have to wait
During the Covid-19 pandemic, vaccines were the main line of defense. Startlingly effective shots quickly…
Maryland takes first steps to cap drug costs
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Opinion: What clinical real-world data can deliver
Thanks to new regulatory frameworks like the Food and Drug Administration’s Breakthrough Therapy designation, drugs…
Lilly doubles down on radiopharma
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: AltruBio raises $225 million to develop ulcerative colitis drug and other immune checkpoint enhancers
Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have…
STAT+: AI & drug discovery: A biotech CEO, a scientist, and a venture capitalist separate hype from reality
Artificial intelligence is a rapidly improving technology. But its progress in drug development faces an…
AstraZeneca antibody reduced Covid-19 risk in immunocompromised
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: NVIDIA’s Kimberly Powell touts progress on AI in drug discovery
SAN FRANCISCO — In the world of drug discovery, AI progress is often measured by…
Blackstone wants in on red-hot immunology market
The need-to-know this morning Biogen and Ionis Pharmaceuticals are ending their development of an experimental drug for ALS based on…
STAT+: Obesity drug from Roche succeeds in early test, sending company shares up
LONDON — Roche on Thursday said its recently acquired experimental obesity medication helped people lose…
Leqembi gets closer to being offered as an injection
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Is Novavax a new meme stock?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
We now know Tome’s gene editing target
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The public wants Medicare to cover obesity drugs
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Yet another big financing round in immunology
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: In fundamental advance, Google says AlphaFold 3 can map a vast universe of biomolecules
Google on Wednesday unveiled an artificial intelligence tool capable of predicting the structure and interaction…
Pharma has over $500B in capital for deals
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Life science leaders on how to make drug development less expensive, slow, and risky
Drug development is essentially a long, expensive bet: Ninety percent of drugs fail during clinical…
Vertex starts gene therapy Casgevy in five patients
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Merck may have a competition for ever-scarce BCG
Want to stay on top of the science and politics driving biotech today? Sign up to get…
ICER casts doubt on Sarepta’s DMD gene therapy
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The biotech news you need to read this morning
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Experimental gene therapy seems to alleviate skeletal defects tied to rare inherited disease, study shows
LONDON — In 2021, a team of Italian researchers reported that an experimental gene therapy…
The latest government crackdowns on biotech you need to know
Want to stay on top of the science and politics driving biotech today? Sign up to get…
San Diego’s life sciences sector struggles for financial security
LA JOLLA, Calif. — About a half century ago, a barren ocean bluff here started…
Opinion: Creating the next wave of antibody therapies requires innovative collaboration
Next-generation broadly neutralizing antibodies (bnAbs) have the potential to transform the fight against global health…
FDA wants to hear your thoughts on advisory committees
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: After AI protein folding, David Baker’s lab identifies millions of smaller drug candidates
University of Washington professor David Baker has made a name for himself by borrowing computer…
STAT+: Why a British hospital, and not a drugmaker, is trying to get a rare disease therapy approved
LONDON — Claire Booth, a gene therapy researcher in London, had hoped that a biotech…
STAT+: Day One drug for common childhood brain tumor approved by FDA
Day One Biopharmaceuticals said Tuesday the Food and Drug Administration approved its pill for one…